Altimmune, Inc., a clinical-stage biotechnology company known for its cutting-edge intranasal vaccines and immunotherapy platforms, is reportedly in advanced talks for a potential acquisition by Novo Holdings, the investment arm of Danish pharmaceutical giant Novo Nordisk. Sources familiar with the matter have suggested that the deal could be valued between $7 billion and $10 billion.
Altimmune, Inc., a clinical-stage biotechnology company known for its cutting-edge intranasal vaccines and immunotherapy platforms, is reportedly in a ...
Satisfied Users & 
Approved Press Releases
